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To the Editor, 25 
 26 
We reflect on the current and anticipated future impact of the COVID-19 pandemic on 27 
tuberculosis  (TB) control in India. According to the latest figures from the WHO, India 28 
accounts for a quarter of all global & multidrug-resistant (MDR) TB cases [1]. Many cases 29 
remain undiagnosed, or when diagnosed are not treated, or appropriately notified. As a result,  30 
only 58% of overall estimated new and relapsing TB cases are notified in India,   [1]. Despite 31 
concerted efforts driven mainly by the UN’s Sustainable Development Goals, WHO End TB 32 
Strategy and the Government of India’s  National Strategic Plan (NSP) to eliminate TB by 33 
2025, the incidence of TB has been declining slowly.We have previously reported a high 34 
prevalence of latent TB in the Nagpurian population [2]. Risk factors such as poverty, low 35 
socioeconomic status, malnutrition with impaired immunity, poor housing, and inadequate 36 
ventilation were significantly associated with developing latent TB, and active case conversion.  37 
Since the nationwide lockdown commenced on March 25th, the number of COVID-19 cases in 38 
India has continued to surge. The number of confirmed cases of SARS-CoV-2  infection rose 39 
to 566,840 with 16,893 deaths as of June 30th, making it the country with the fourth highest 40 
number of reported cases. [3] 41 
Due to current shifts in economic, and political priorities towards COVID-19 containment, it 42 
is our contention that national efforts to tackle TB are likely to be adversely affected. In terms 43 
of economic impact, an estimated 140 million Indian people have already lost their jobs during 44 
the current crisis. Lost earnings have been particularly harmful to the most marginalized, and 45 
impoverished communities, bolstering poverty, and malnutrition further, both of which are 46 
major risk factors that predispose to TB in rural and urban communities. As India continues to 47 
battle the coranovirus pandemic, the current lockdown is already leading to debilitating effects 48 
on TB services with limited access to health care, anti-tuberculous drugs, and disruption of 49 
treatment services. The Stop TB partnership modelling analysis has assessed the potential 50 
effects of lockdown on TB incidence and mortality over the next 5 years in high burden 51 
settings. In the case of India, lockdown has resulted in a striking 80% reduction in TB 52 
notification rates [4].  53 
Consequently, it is anticipated that a huge number of cases will remain undiagnosed, and 54 
untreated, further fueling TB transmission rates among household contacts. A report suggests 55 
that  India will need to manage 232,665 excess TB cases for every month of lockdown, and 56 
71,290 excess TB deaths which is significantly higher compared to excess cases predicted for 57 
other high burden countires such Kenya (3,980) and Ukraine (1,058)  [4]. In terms of  multidrug 58 
resistant TB (MDR-TB), and considering an incidence of 5% (out of overall reported TB 59 
cases),  India will see an excess 11,663 MDR-TB cases per month during the pandemic. It is 60 
therefore essential that in addition to the restoration of normal TB services, supplementary 61 
measures are instigated, with a focus on reducing the prevalent pool of TB in endemic settings. 62 
Such measures may involve a combination of intensive community engagement, maintaining 63 
awareness of the importance of TB services and enhanced active case-finding efforts, including 64 
rapid scale-up of contact tracing where possible to compensate for missed diagnoses imposed 65 
by the lockdown. Additional innovative approaches such as the use of digital technology and 66 
other tools will be encouraged.   67 
In terms of social distancing, clearly challenges lie ahead. TB patients often live in crowded 68 
conditions with poor hygiene, which increases their risk of getting COVID-19.  It is thus vital 69 
that TB patients can be isolated to minimize the occurrence of severe co-infections in view of 70 
their depressed immunity & hospitalizations. Such enhanced social distancing measures should 71 
be targeted more clearly towards those with MDR-TB.While current available literature on 72 
COVID-19 infection in TB patients remains limited, it is anticipated that co-infections  will 73 
lead to poorer treatment outcomes. Concerningly, recent reports suggest that influenzal co-74 
infection may be capable of exploiting and altering innate immune defense mechanisms, 75 
thereby exacerbating pulmonary TB and promoting the likelihood of developing secondary 76 
bacterial infections [5]. 77 
Thus, a robust integrated effort from policy makers, state and national government and NGOs 78 
is now needed to reduce the burden of tuberculosis through urgently maintaining continuity of 79 
essential services, accelerated surveillance of vulnerable populations and asymptomatic 80 
contacts to identify high-risk groups, and through gathering high quality molecular 81 
epidemiologic research. 82 
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